Mirum Pharmaceuticals (NASDAQ:MIRM) reported quarterly losses of $(13.43) per share which missed the analyst consensus estimate of $(0.37) by 3529.73 percent. This is a 4376.67 percent decrease over losses of $(0.30) per share from the same period last year. The company reported quarterly sales of $159.882 million which beat the analyst consensus estimate of $149.535 million by 6.92 percent. This is a 43.26 percent increase over sales of $111.600 million the same period last year.